1	Germline mutations in young-onset sporadic pituitary macroadenomas: a multigene panel
2	analysis
3	
4	Leonor M. Gaspar ¹ , Catarina I. Gonçalves ¹ , Ema L. Nobre ² , Fernando Fonseca ³ , Cláudia Amaral ⁴ ,
5	João S. Duarte ⁵ , Luísa Raimundo ⁶ , Catarina Saraiva ⁵ , Luísa Cortez ³ , Olinda Marques ⁷ , Manuel C.
6	Lemos ^{1*}
7	
8	¹ CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
9	² Serviço de Endocrinologia, Diabetes e Metabolismo, Hospital de Santa Maria, Unidade Local de
10	Saúde Santa Maria, Lisboa, Portugal
11	³ Serviço de Endocrinologia, Hospital de Curry Cabral, Unidade Local de Saúde São José, Lisboa,
12	Portugal
13	⁴ Serviço de Endocrinologia, Hospital de Santo António, Centro Hospitalar Universitário do Porto,
14	Porto, Portugal
15	⁵ Serviço de Endocrinologia, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa,
16	Portugal
17	⁶ Serviço de Endocrinologia e Diabetes, Hospital Garcia de Orta, Almada, Portugal
18	⁷ Serviço de Endocrinologia, Hospital de Braga, Braga, Portugal
19	
20	* Corresponding author:
21	Manuel C. Lemos
22	CICS-UBI, Health Sciences Research Centre
23	University of Beira Interior
24	6200-506 Covilhã, Portugal
25	Email: mclemos@fcsaude.ubi.pt
26	NODER Chip Depth Order Office Depth Order Offic

Short title: Germline mutations in pituitary adenomas

Keywords: Pituitary adenoma; Genetics; Mutation

Word count 2701 (excluding abstract, references, table, figure legend, and supplemental material).

Abstract

35

36

37

38

39

40

41

42

43 44

45 46

47

48

49

50

51

52

53

54

55

56

57

Objective: Mutations in several genes have been associated with familial forms of pituitary adenomas. Sporadic pituitary adenomas (i.e. with no family history or coexistent endocrine tumours) are also occasionally found to result from germline mutations in these genes, especially in young patients with larger tumours. The aim of this study was to determine the frequency of germline mutations in patients with young-onset sporadic pituitary macroadenomas. Methods: A cohort of 225 Portuguese patients with sporadic pituitary macroadenomas diagnosed before the age of 40 years was studied by whole exome sequencing (WES) followed by the analysis of a virtual panel of 29 genes that have been associated with predisposition to pituitary adenomas. Results: Pathogenic and likely pathogenic variants were identified in 16 (7.1%) of patients. The affected genes were AIP (n=4), PMS2 (n=4), MEN1 (n=2), VHL (n=2), CDH23 (n=1), MSH2 (n=1), SDHB (n=1), and TP53 (n=1). In patients diagnosed under the ages of 30 and 18 years, the frequency of mutations increased to 9.0% and 12.0%, respectively. Conclusion: This is so far the largest multigene analysis of patients with young-onset sporadic pituitary macroadenomas. We confirmed the AIP as the most frequently involved gene, but also uncovered rarer genetic causes of pituitary adenomas, including the first independent confirmation of a role of the CDH23 gene. The results may contribute to a better understanding of the genetic landscape of these tumours and help to decide which genes to include in the genetic screening of patients with young-onset pituitary macroadenomas.

Introduction

58

59

60

61

62

63

64

65

66

67

68 69

70

71

72

73

74

75

76

77

78

79

80

81

82

Most pituitary adenomas occur sporadically and are often attributed to acquired somatic and epigenetic mutations (1). However, a subset of cases arises within a familial context, either as part of syndromic diseases or as familial isolated pituitary adenomas (FIPA), which are caused by pathogenic germline mutations (2). Tumours within familial settings tend to be more aggressive, manifesting at a younger age, with larger sizes, increased invasiveness, and resistance to standard treatments (3). An expanding list of genes, including AIP, CABLES1, CDH23, CDKN1A, CDKN1B, CDKN2B, CDKN2C, DICER1, GNAS, GPR101, MAX, MEN1, MLH1, MSH2, MSH6, NF1, PMS2, PRKACA, PRKACB, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TP53, USP8, and VHL, has been identified with germline or mosaic mutations predisposing individuals to pituitary adenomas (4-6). Identifying these genetic alterations is not only crucial for accurate diagnosis and personalized treatment, but also provides valuable insights into the molecular pathways disrupted in these tumours (7). While sporadic cases traditionally lack a clear hereditary component, several studies have shown that a variable proportion of these cases harbour germline mutations (8). The most extensively studied gene is AIP, which was first associated with FIPA (9), but later found to be mutated in many apparently sporadic cases, particularly among patients of younger ages and with larger tumours (10). We recently screened a cohort of patients diagnosed with young-onset sporadic pituitary macroadenomas for AIP mutations (11). This revealed the presence of AIP mutations in 1.8%, 3.4% and 5.0% of patients diagnosed under the ages of 40, 30 and 18 years, respectively (11). Building upon this, we have now employed next-generation sequencing to expand the genetic screening to all genes with germline mutations that have so far been associated with familial isolated or syndromic pituitary adenomas.

Materials and Methods

Subjects

83

84

103

104

105

106

107

108

109

110

111

112

113

114

This was a follow-up study of a Portuguese multicentre cohort that had been previously studied 85 86 by conventional (Sanger) sequencing of the AIP gene (11). A total of 225 patients were available 87 for this study. Inclusion criteria were patients with macroadenomas (tumour greater diameter ≥ 1 cm) diagnosed under the age of 40 years. Exclusion criteria were patients with a family history 88 89 of pituitary adenomas (i.e. affected first or second degree family member) or with evidence of 90 a syndromic form of pituitary adenoma. Mean age (± standard deviation) at diagnosis was 29.1 91 ± 7.3 years, 122 patients were under 30 years at diagnosis, and 25 patients were under 18 years 92 at diagnosis. Gender distribution was 116 (51.6%) females and 109 (48.4%) males. Tumour 93 classification was based on histological examination or, in the case of prolactinomas, by clinical, 94 hormonal and radiological examination. Eighty-one (36.0%) patients had prolactinomas, 62 95 (27.6%) had somatotrophinomas, 37 (16.4%) had non-functioning pituitary adenomas, 16 (7.1%) had mixed-secreting pituitary adenomas, 15 (6.7%) had corticotrophinomas, seven (3.1%) had 96 97 gonadotrophinomas, one (0.4%) had a thyrotrophinoma, and six (2.7%) had adenomas with 98 undetermined histology. The control population comprised 298 Portuguese individuals (50 99 healthy blood donors and 248 patients with unrelated disorders). The study was approved by 100 the Ethics Committee of the Faculty of Health Sciences, University of Beira Interior (Ref: CE-UBI-101 Pj-2018-027 and CE-FCS-2011-003) and written informed consent was obtained from all 102 subjects.

Whole exome sequencing (WES) and virtual gene panel

Genomic deoxyribonucleic acid (DNA) was extracted from the peripheral blood leukocytes of each patient and used for WES analysis according to previously described methods (12). A virtual gene panel was created, consisting of 29 genes in which germline or mosaic mutations have been reported in patients with familial isolated or syndromic pituitary adenomas (4-6), namely AIP (NM_003977.3), CABLES1 (NM_001100619.2), CDH23 (NM_022124.5), CDKN1A (NM_078467.3), CDKN1B (NM_004064.4), CDKN2B (NM_004936.4), CDKN2C (NM_001262.3), DICER1 (NM_177438.3), GNAS (NM_000516.7), GPR101 (NM_054021.1), MAX (NM_002382), MEN1 (NM_130799.2), MLH1 (NM_000249.4), MSH2 (NM_000251.3), MSH6 (NM_000179.3), NF1 (NM_000267.3), PMS2 (NM_000535.7), PRKACA (NM_002730.4), PRKACB (NM_182948.4), PRKAR1A (NM_002734.5), RET (NM_020975.4), SDHA (NM_004168.3), SDHAF2 (NM_017841.2),

SDHB (NM_003000.3), SDHC (NM_003001.5), SDHD (NM_003002.3), TP53 (NM_000546.6),

USP8 (NM 005154.5), and VHL (NM 000551.3).

Interpretation of genetic variants

Genetic variants were filtered according to the following cumulative criteria: 1) Location in one of the 29 genes previously implicated in pituitary adenomas; 2) Location in coding transcripts used by the Human Genome Mutation Database (HGMD) (13); 3) Location in coding exons or up to ten nucleotides adjacent to the coding exons; and 4) Population allele frequency less than 0.001 in the Genome Aggregation Database (gnomAD) and 1000 Genomes database (14). The variants selected by these criteria were classified as benign (B), likely benign (LB), variant of uncertain significance (VUS), likely pathogenic (LP) or pathogenic (P), according to American College of Medical Genetics and Genomics (ACMG) criteria (15) and ClinGen recommendations (16), using a web-based variant interpretation tool (Franklin by Genoox, reference hg19, https://franklin.genoox.com/, accessed on 30 March 2024). Filtered variants were screened in an in-house database of 298 Portuguese control individuals to assess the possibility of variants being population-specific common polymorphisms.

Validation of genetic variants by Sanger sequencing

Variants classified as pathogenic and likely pathogenic were confirmed by conventional Sanger sequencing using a semi-automated DNA sequencer (STAB VIDA, Caparica, Portugal; and ABI 3730XL, Applied Biosystems; Thermo Fisher Scientific, Waltham, MA, USA).

Results 137 138 Rare sequence variants identified in the 29 analysed genes 139 A total of 154 (141 different) rare sequence variants (population allele frequency <0.001) were 140 identified in 114 of the 225 patients. These variants were found in 25 of the 29 analysed genes and included three pathogenic, 13 likely pathogenic (11 different), 63 VUS (56 different), 64 141 142 likely benign (61 different) and 11 benign (10 different) (Supplemental Data 1). All rare sequence 143 variants were identified in the heterozygous state. 144 145 Pathogenic and likely pathogenic variants 146 Pathogenic and likely pathogenic variants were identified in 16 (7.1%) patients with young-onset 147 sporadic pituitary macroadenomas. These consisted of four AIP gene mutations (previously 148 reported by us (11)) (p.Ser53ThrfsTer36, p.Arg81Ter, p.Leu115TrpfsTer41, and p.Glu246Ter), four PMS2 mutations (three patients with p.Asn335Ser, and one with p.Asp486GlufsTer109), 149 150 two MEN1 mutations (p.Trp183Ter, and p.Arg314 Asp315del), two VHL mutations 151 (p.Lys196Glu, and p.Glu52Ter), one CDH23 mutation (p.Glu2520Lys), one MSH2 mutation 152 (p.Arg524His), one SDHB mutation (p.Ile127Leu), and one TP53 mutation (p.Arg282Gln) (Table 153 1 and Figure 1). 154 155 Prevalence of mutations according to age of diagnosis 156 The prevalence of mutations was higher in patients with younger ages at diagnosis. The 157 prevalence of mutations in patients diagnosed up until the age of 40, 30 and 18 years was 7.1% (16/225), 9.0% (11/122), and 12.0% (3/25), respectively. 158 159 160 Clinical characteristics of patients with mutations 161 The clinical characteristics of the 16 patients with identified mutations are presented in Table 1. 162 Patients had no personal history of additional tumours or other syndromic features at the time 163 of inclusion in the study. However, two patients with MEN1 mutations were found to have 164 hyperparathyroidism during or after undertaking the genetic studies.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Discussion Our analysis of 225 patients with young-onset sporadic pituitary macroadenomas showed that 16 (7.1%) patients had germline mutations in genes that are associated with familial forms of pituitary adenomas. These mutations involved the AIP (1.8% of patients), PMS2 (1.8%), MEN1 (0.9%), VHL (0.9%), CDH23 (0.4%), MSH2 (0.4%), SDHB (0.4%), and TP53 (0.4%) genes. The AIP gene is associated with FIPA (9), but has also been extensively studied in patients with sporadic pituitary adenomas. The prevalence of AIP germline mutations in patients with sporadic pituitary macroadenomas under the age of 40 has been reported to vary from 0% to 18% (11), depending of the country of origin, clinical characteristics of the cohort, and criteria used for the classification of genetic variants. We found four (1.8%) patients with AIP mutations, which were frameshift (p.Ser53ThrfsTer36, and p.Leu115TrpfsTer41) and nonsense (p.Arg81Ter, and p.Glu246Ter) mutations expected to lead to a premature stop codon and to the formation of a shorter protein or to nonsense-mediated decay (17). These AIP mutations were all found in patients with GH-secreting adenomas, in agreement with the higher prevalence of AIP mutations in this tumour type (18). These results confirm the results of our previous Sanger sequencing of the AIP gene in this cohort of patients (11). The PMS2 gene is associated with Lynch syndrome (19), which is characterised by the occurrence of a variety of tumours that include colorectal, endometrial, ovarian and gastric cancers (20). Although some cases of aggressive pituitary tumours have been reported in patients with Lynch syndrome (21-23), the prevalence of PMS2 mutations in sporadic pituitary adenomas has never been reported before. We found four (1.8%) patients with PMS2 mutations, with no other apparent manifestations of Lynch syndrome. These consisted of a previously reported (24) missense (p.Asn335Ser) mutation that was identified in three unrelated patients, diagnosed with a somatotrophinoma, prolactinoma and non-functioning pituitary adenoma, and a novel frameshift (p.Asp486GlufsTer109) mutation in a patient with a prolactinoma. Thus, our study suggests that the PMS2 gene has a more important role in pituitary tumorigenesis than previously acknowledged. The MEN1 gene is associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome, which is characterised by the occurrence of parathyroid, pancreatic and pituitary tumours (25, 26). MEN1 mutations are occasionally found in patients with pituitary adenomas without other MEN1 manifestations. A previous study identified MEN1 mutations in 3.4% of patients with sporadic pituitary macroadenomas diagnosed before the age of 30 (27). Our study found two (0.9%) patients with MEN1 mutations, which consisted of a previously reported (26) nonsense

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

mutation (p.Trp183Ter) and a novel in-frame deletion (p.Arg314 Asp315del). Both patients had mixed GH-secreting adenomas. It is interesting to note that although there were no other apparent manifestations of the MEN1 syndrome at the time of the diagnosis of the pituitary adenoma, both patients were eventually found to have hyperparathyroidism during or after undertaking the genetic studies. The VHL gene is associated with the Von Hippel-Lindau (VHL) syndrome, which is characterised by tumours in several organs, such as retinal and central nervous system haemangioblastomas, pheochromocytomas and clear-cell renal carcinomas (28). Pituitary adenomas have also been described in patients with the VHL syndrome (29). However, the prevalence of VHL mutations in sporadic pituitary adenomas has not been reported. We found two (0.9%) patients with VHL mutations, with no other apparent manifestations of the VHL syndrome. These consisted of a previously reported (30) nonsense (p.Glu52Ter) mutation in a patient with a prolactinoma and a previously reported (31) missense (p.Lys196Glu) mutation in a patient with a thyrotrophinoma. The latter mutation was previously reported in homozygosity in a patient with autosomal recessive congenital erythrocytosis, but with no evidence of the VHL syndrome (31). Therefore, it remains to be clarified if heterozygosity for this particular mutation, as found in our patient, can cause the VHL syndrome. The CDH23 gene is associated with the autosomal recessive Usher syndrome, which is characterized by congenital deafness (32). However, a study by Zhang et al. (33) demonstrated the presence of CDH23 heterozygous mutations in 33% and 12% of familial and isolated pituitary adenomas, respectively. So far, these results have not been independently confirmed. Furthermore, there have been no reports of a higher incidence of pituitary adenomas in patients with Usher syndrome or in their heterozygous relatives. We found one (0.4%) patient with a GHsecreting adenoma and a previously reported (34) CDH23 missense mutation (p.Glu2520Lys). Thus, our study represents the first independent confirmation of a role of CDH23 in the development of pituitary adenomas. The MSH2 gene is also associated with Lynch syndrome (35, 36) and some affected patients have been reported to have aggressive pituitary adenomas (21-23). We found one (0.4%) patient with a previously reported (37) MSH2 missense mutation (p.Arg524His), who had a prolactinoma with no other apparent manifestations of Lynch syndrome. The SDHB gene is associated with paragangliomas and pheochromocytomas (38). Pituitary adenomas occasionally occur in association with these (3PA, Phaeochromocytoma, Paraganglioma and Pituitary adenoma association) (39). However, the prevalence of SDHB

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263264

265

mutations in sporadic pituitary adenomas is unknown. A French study of 263 patients with sporadic pituitary adenomas revealed two mutations in the SDHA gene, one in the SDHC gene, but none in SDHB (40). We found one (0.4%) patient with a previously reported (41) SDHB missense mutation (p.Ile127Leu), who had a prolactinoma without any other syndromic manifestations. The TP53 gene is considered the most mutated tumour suppressor gene in human cancers (42). Germline mutations in this gene are associated with the Li-Fraumeni syndrome, which predisposes to soft tissue sarcomas, osteosarcoma, breast cancer, leukaemia, and adrenocortical carcinoma (43). The role of the TP53 gene in pituitary adenomas is less clear. The TP53 gene was included in our gene panel because a recent review (6) listed it as one of the genes in which germline mutations are implicated in pituitary adenomas. However, although somatic mutations in TP53 have been reported in pituitary adenomas (1), we found no reports of germline mutations in patients with these tumours. Nevertheless, in our study, we found one (0.4%) patient with a previously reported (44) TP53 germline missense mutation (p.Arg282Gln), who had a corticotrophinoma without any other syndromic manifestations. Thus, our study reports for the first time a TP53 germline pathogenic mutation in a patient with a pituitary adenoma. None of the patients included in our study had other coexistent tumours or syndromic features or family history that would raise the suspicion of a germline mutation. The unexpected identification of germline mutations in a subset of patients with sporadic tumours could have several explanations. First, family history was self-reported by the patients and may have been inaccurate or incomplete. Second, the lack of other affected family members could have been due to incomplete penetrance of the mutation or to a de novo mutation in the patient. Third, other syndromic manifestations could have been missed on clinical screening or absent due to variable expression of the mutation. Importantly, our identification of patients with germline mutations will improve their clinical management, allow the screening of additional syndromic manifestations, and allow the identification of additional affected family members that can be screened for the disorder (6). Previous studies of sporadic pituitary adenomas have mainly focused on the AIP gene, as this is the most commonly mutated gene in such cases (8). Only three other studies performed gene panel analyses in patients with sporadic pituitary adenomas, but with a limited number of genes (≤ 9) that did not include for example the VHL, PMS2 or CDH23 genes (40, 45, 46). Nevertheless, these studies were able to identify pathogenic variants in 3.8% to 10% of patients with youngonset sporadic pituitary adenomas.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

In our study, we analysed the largest panel of genes so far in patients with sporadic pituitary adenomas. We confirmed the AIP as the most frequently involved gene in these patients, but also uncovered rarer genetic causes of pituitary adenomas. Altogether, germline mutations were present in 7.1% of our patients diagnosed with sporadic macroadenomas under the age of 40 years. However, this proportion increased to 9.0% and 12.0%, in patients diagnosed under the ages of 30 and 18 years, respectively. This is in agreement with the general observation that tumours arising in younger ages are more likely to have a genetic cause. The existence of subsets of patients at higher risk of harbouring germline mutations has led to recommendations for AIP and MEN1 mutation testing in patients with pituitary macroadenomas diagnosed under the age of 30 (10, 27) or 40 years (47). However, there are currently no recommendations for additional genetic testing of sporadic pituitary adenomas that have been shown to be AIP and MEN1 mutation-negative. Our study suggests that testing such patients for a wider gene panel may uncover further cases of genetically-determined pituitary adenomas. Our study has some limitations. First, we did not look for copy number variants or mutations in non-coding genomic regions. Second, we did not look for mutations in other genes beyond those that have so far been associated with pituitary adenomas. Third, we found a large number of VUS, for which there is currently insufficient evidence for an association with the disorder, but that may need reclassification over time (48). In conclusion, we found a prevalence of 7.1% germline mutations in patients with young-onset pituitary macroadenomas. These include mutations in the AIP, MEN1, MSH2, PMS2, SDHB, TP53 and VHL genes and the first independent confirmation of a mutation in the CDH23 gene. Our results may contribute to a better understanding of the genetic landscape of these tumours and help to decide which genes to include in the genetic screening of patients with young-onset pituitary macroadenomas.

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

Supplementary data Supplementary data 1. Rare sequence variants identified in patients with young-onset sporadic pituitary macroadenomas. **Conflict of interest** The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. **Funding** This research was funded by the Portuguese Foundation for Science and Technology (FCT, project grants PTDC/MEC-MET/29489/2017 and UIDB/00709/2020). LM Gaspar was the recipient of a PhD fellowship from FCT (SFRH/BD/147160/2019). **Acknowledgements** The authors are grateful to the following clinicians for collecting patient samples and clinical data: Ana Agapito (Lisboa), Ana Monteiro (Braga), Ana Palha (Lisboa), Bernardo Pereira (Ponta Delgada), Daniela Cavaco (Lisboa), Davide Carvalho (Porto), Hélder Simões (Lisboa), Henrique Luiz (Almada), Inês Barros (Braga), Inês Damásio (Lisboa), Isabel Inácio (Porto), Joana Pereira (Lisboa), João Anselmo (Ponta Delgada), Maria João Bugalho (Lisboa), Maria Manuel Silva (Porto), Maria Salomé (Lisboa), Mariana Barbosa (Braga), Rita Santos (Lisboa), Sara Donato (Lisboa), Sara Pinheiro (Lisboa), Sílvia Paredes (Braga), Teresa Martins (Coimbra), Teresa Rego (Lisboa), Tiago Silva (Lisboa), and Valeriano Leite (Lisboa). Data availability statement The data from this study are available from the corresponding author upon reasonable request. **Author contribution statement** LM Gaspar and CI Gonçalves contributed to the acquisition, analysis and curation of genetic data, and writing of the original draft of the manuscript. E Nobre, F Fonseca, C Amaral, J Sequeira Duarte, L Raimundo, C Saraiva, L Cortez, and O Margues contributed to the recruitment and

clinical studies of the patients. MC Lemos contributed to the conceptualization, funding acquisition, resources and supervision of the project. All authors contributed to reviewing and editing and approved the final version of the manuscript.

References

325

- 327 1. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical Biology of
- 328 the Pituitary Adenoma. Endocr Rev. 2022;43(6):1003-37.
- 329 2. De Sousa SMC, Lenders NF, Lamb LS, Inder WJ, McCormack A. Pituitary tumours:
- molecular and genetic aspects. J Endocrinol. 2023;257(3).
- 331 3. Armeni E, Grossman A. The Spectrum of Familial Pituitary Neuroendocrine Tumors.
- 332 Endocr Pathol. 2023;34(1):57-78.
- 333 4. Vandeva S, Daly AF, Petrossians P, Zacharieva S, Beckers A. Somatic and germline
- mutations in the pathogenesis of pituitary adenomas. European journal of endocrinology.
- 335 2019;181(6):R235-R54.
- 336 5. Shen AJJ, King J, Scott H, Colman P, Yates CJ. Insights into pituitary tumorigenesis: from
- 337 Sanger sequencing to next-generation sequencing and beyond. Expert review of endocrinology
- 338 & metabolism. 2019;14(6):399-418.
- 339 6. Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary
- 340 disease. Clinical endocrinology. 2022;97(4):424-35.
- 341 7. Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary
- 342 Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
- 343 Neuroendocrinology. 2022;112(1):15-33.
- 344 8. lacovazzo D, Hernandez-Ramirez LC, Korbonits M. Sporadic pituitary adenomas: the role
- 345 of germline mutations and recommendations for genetic screening. Expert review of
- 346 endocrinology & metabolism. 2017;12(2):143-53.
- 347 9. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary
- adenoma predisposition caused by germline mutations in the AIP gene. Science (New York, NY).
- 349 2006;312(5777):1228-30.
- 350 10. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, et al. High
- 351 prevalence of AIP gene mutations following focused screening in young patients with sporadic
- 352 pituitary macroadenomas. European journal of endocrinology. 2011;165(4):509-15.

- 353 11. Gaspar LM, Goncalves CI, Saraiva C, Cortez L, Amaral C, Nobre E, et al. Low frequency of
- 354 AIP mutations in patients with young-onset sporadic pituitary macroadenomas. J Endocrinol
- 355 Invest. 2023;46(11):2299-307.
- 356 12. Goncalves CI, Carrico J, Bastos M, Lemos MC. Disorder of Sex Development Due to 17-
- 357 Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: A Case Report and Review of 70
- Different HSD17B3 Mutations Reported in 239 Patients. Int J Mol Sci. 2022;23(17):10026.
- 359 13. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene
- 360 Mutation Database: towards a comprehensive repository of inherited mutation data for medical
- 361 research, genetic diagnosis and next-generation sequencing studies. Hum Genet.
- 362 2017;136(6):665-77.
- 363 14. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational
- 364 constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-
- 365 43.
- 366 15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
- for the interpretation of sequence variants: a joint consensus recommendation of the American
- 368 College of Medical Genetics and Genomics and the Association for Molecular Pathology.
- 369 Genetics in medicine: official journal of the American College of Medical Genetics.
- 370 2015;17(5):405-24.
- 371 16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of
- 372 computational tools for missense variant pathogenicity classification and ClinGen
- recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022;109(12):2163-77.
- 374 17. Karousis ED, Muhlemann O. The broader sense of nonsense. Trends Biochem Sci.
- 375 2022;47(11):921-35.
- 376 18. Caimari F, Hernandez-Ramirez LC, Dang MN, Gabrovska P, Iacovazzo D, Stals K, et al. Risk
- 377 category system to identify pituitary adenoma patients with AIP mutations. Journal of medical
- 378 genetics. 2018;55(4):254-60.
- 379 19. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of
- two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371(6492):75-80.

- 381 20. Biller LH, Creedon SA, Klehm M, Yurgelun MB. Lynch Syndrome-Associated Cancers
- 382 Beyond Colorectal Cancer. Gastrointest Endosc Clin N Am. 2022;32(1):75-93.
- 383 21. Teuber J, Reinhardt A, Reuss D, Hahnel S, Unterberg A, Beynon C. Aggressive pituitary
- adenoma in the context of Lynch syndrome: a case report and literature review on this rare
- 385 coincidence. Br J Neurosurg. 2021:1-6.
- 22. Loughrey PB, Baker G, Herron B, Cooke S, Iacovazzo D, Lindsay JR, et al. Invasive ACTH-
- 387 producing pituitary gland neoplasm secondary to MSH2 mutation. Cancer Genet. 2021;256-
- 388 257:36-9.
- 389 23. Bengtsson D, Joost P, Aravidis C, Askmalm Stenmark M, Backman AS, Melin B, et al.
- 390 Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in
- 391 a Nationwide LS Cohort. The Journal of clinical endocrinology and metabolism.
- 392 2017;102(11):3928-32.
- 393 24. Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-generation
- 394 sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture
- targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305-13.
- 396 25. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR,
- et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (New York,
- 398 NY). 1997;276(5311):404-7.
- 399 26. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of
- 400 the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum
- 401 Mol Genet. 1997;6(7):1177-83.
- 402 27. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, et al. Genetic
- 403 analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget
- 404 MEN1 genetic analysis. European journal of endocrinology. 2013;168(4):533-41.
- 405 28. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-
- 406 Lindau disease tumor suppressor gene. Science (New York, NY). 1993;260(5112):1317-20.
- 407 29. Denes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous
- 408 genetic background of the association of pheochromocytoma/paraganglioma and pituitary

- 409 adenoma: results from a large patient cohort. The Journal of clinical endocrinology and
- 410 metabolism. 2015;100(3):E531-41.
- 411 30. Leonardi E, Martella M, Tosatto SC, Murgia A. Identification and in silico analysis of novel
- 412 von Hippel-Lindau (VHL) gene variants from a large population. Ann Hum Genet. 2011;75(4):483-
- 413 96.
- 414 31. Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C, et al. Molecular study of
- 415 congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less
- than half of the cases (Where is/are the missing gene(s)?). Eur J Haematol. 2013;91(4):361-8.
- 417 32. Bolz H, von Brederlow B, Ramirez A, Bryda EC, Kutsche K, Nothwang HG, et al. Mutation
- of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type
- 419 1D. Nat Genet. 2001;27(1):108-12.
- 420 33. Zhang Q, Peng C, Song J, Zhang Y, Chen J, Song Z, et al. Germline Mutations in CDH23,
- 421 Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary
- 422 Adenomas. Am J Hum Genet. 2017;100(5):817-23.
- 423 34. Cesca F, Bettella E, Polli R, Leonardi E, Aspromonte MC, Sicilian B, et al. Frequency of
- 424 Usher gene mutations in non-syndromic hearing loss: higher variability of the Usher phenotype.
- 425 J Hum Genet. 2020;65(10):855-64.
- 426 35. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human
- 427 mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.
- 428 Cell. 1993;75(5):1027-38.
- 429 36. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a
- 430 mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75(6):1215-25.
- 431 37. Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, et al. Targeted next generation
- 432 sequencing identifies functionally deleterious germline mutations in novel genes in early-
- onset/familial prostate cancer. PLoS Genet. 2018;14(4):e1007355.
- 434 38. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the
- 435 succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and
- 436 to familial paraganglioma. Am J Hum Genet. 2001;69(1):49-54.

- 437 39. O'Toole SM, Denes J, Robledo M, Stratakis CA, Korbonits M. 15 YEARS OF
- 438 PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or
- paragangliomas. Endocr Relat Cancer. 2015;22(4):T105-22.
- 440 40. Mougel G, Lagarde A, Albarel F, Essamet W, Luigi P, Mouly C, et al. Germinal defects of
- SDHx genes in patients with isolated pituitary adenoma. European journal of endocrinology.
- 442 2020;183(4):369-79.
- 443 41. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate
- dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.
- 445 2012;188(6):2063-71.
- 446 42. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers.
- 447 Science (New York, NY). 1991;253(5015):49-53.
- 448 43. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, et al. Germ line p53
- 449 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science
- 450 (New York, NY). 1990;250(4985):1233-8.
- 451 44. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53
- 452 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer.
- 453 2000;82(12):1932-7.
- 454 45. De Sousa SMC, McCabe MJ, Wu K, Roscioli T, Gayevskiy V, Brook K, et al. Germline
- 455 variants in familial pituitary tumour syndrome genes are common in young patients and families
- with additional endocrine tumours. European journal of endocrinology. 2017;176(5):635-44.
- 457 46. Martinez de LaPiscina I, Portillo Najera N, Rica I, Gaztambide S, Webb SM, Santos A, et
- 458 al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary
- adenomas. European journal of endocrinology. 2021;185(4):485-96.
- 460 47. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP
- 461 mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center
- 462 cohort of 443 patients. The Journal of clinical endocrinology and metabolism. 2012;97(4):E663-
- 463 70.

- 464 48. Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The Challenge of Genetic
- 465 Variants of Uncertain Clinical Significance : A Narrative Review. Ann Intern Med.
- 466 2022;175(7):994-1000.

- 467 49. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, et al. The role
- of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary
- adenomas. The Journal of clinical endocrinology and metabolism. 2008;93(6):2390-401.
- 470 50. Daly AF, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS, et al. AIP-mutated
- 471 acromegaly resistant to first-generation somatostatin analogs: long-term control with
- pasireotide LAR in two patients. Endocrine connections. 2019;8(4):367-77.

 Table 1. Clinical and genetic characteristics of 16 patients with pathogenic (P) and likely pathogenic (LP) variants.

Gene (transcript)	Patient number (id)	Sex	Age at diagnosis (yr)	Type of adenoma (hormones produced)	Size of adenoma (mm)	Variant (nucleotide change, protein change) (a)	Effect	Allele frequency in GnomAD	Allele frequency in Portuguese controls	ACMG classification (criteria) (b)	Previous report
AIP (NM_003977.3)	1 (8215)	F	19-30	GH	20	c.158_165delGCCGGGCT, p.Ser53ThrfsTer36	Frameshift deletion	0	0	LP (PVS1, PM2)	(11)*
	2 (7879)	М	19-30	GH	26	c.241C>T, p.Arg81Ter	Nonsense	0	0	P (PVS1, PM2, PS4)	(49) (11)*
	3 (7329)	M	≤18	GH/PRL	14	c.343delC, p.Leu115TrpfsTer41	Frameshift deletion	0	0	LP (PVS1, PM2)	(50) (11)*
	4 (7632)	F	19-30	GH	28	c.736G>T, p.Glu246Ter	Nonsense	0	0	LP (PVS1, PM2)	(11)*
<i>CDH23</i> (NM_022124.5)	5 (7791)	М	19-30	GH	25	c.7558G>A, p.Glu2520Lys	Missense	0	0	LP (PS4, PM2, PP3, PP5)	(34)
<i>MEN1</i> (NM_130799.2)	6 (7850)	M	31-40	GH/PRL	60	c.548G>A, p.Trp183Ter	Nonsense	0	0	P (PVS1, PS4, PP5, PM2)	(26)
	7 (7971)	F	19-30	GH/PRL/TSH	40	c.940_945delCGGGAT, p.Arg314_Asp315del	In-frame deletion	0	0	LP (PM1, PM2, PM4)	None
<i>MSH2</i> (NM_000251.3)	8 (7642)	F	19-30	PRL	>10	c.1571G>A, p.Arg524His	Missense	0.000011	0	LP (PM2, PM5, PP3)	(37)
<i>PMS2</i> (NM_000535.7)	9 (8072)	М	31-40	GH	>10	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	10 (8094)	F	31-40	PRL	31	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	11 (8095)	F	31-40	Non- functioning	40	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	12 (7648)	М	19-30	PRL	>20	c.1458delC, p.Asp486GlufsTer109	Frameshift deletion	0	0	LP (PVS1, PM2)	None
<i>SDHB</i> (NM_003000.3)	13 (7887)	F	19-30	PRL	20	c.379A>C, p.lle127Leu	Missense	0.000004	0	LP (PM1, PM2, PM5, PP2, PP3)	(41)

<i>TP53</i> (NM_000546.6)	14 (8079)	F	31-40	ACTH	14	c.845G>A, p.Arg282Gln	Missense	0.000004	0	LP (BS3, PM2, PM5, PM1, PP3, PP5)	(44)
<i>VHL</i> (NM_000551.3)	15 (6906)	F	≤18	PRL	>10	c.154G>T, p.Glu52Ter	Nonsense	0.000018	0	LP (PVS1, PM2)	(30)
	16 (7792)	М	≤18	TSH	10	c.586A>G, p.Lys196Glu	Missense	0	0	P (PM1, PM2, PM3, PP2, PP3, PP5)	(31)

id, identification (anonymization code not known to anyone outside the research group); F, female; M, male; yr, years (presented as age range to protect patient privacy); FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; PRL, prolactin; TSH, thyroid stimulating hormone; mm, millimeters; GnomAD, Genome Aggregation Database (v2.1.1). (a) All variants were heterozygous. (b) American College of Medical Genetics and Genomics (ACMG) classification of variants (P, pathogenic; LP, likely pathogenic) was based on the evidence for pathogenicity (very strong (PVS1), moderate (PM1–6), or supporting (PP1–5)). ACMG classifications were based on the web-based variant interpretation tool Franklin (Genoox Ltd, https://franklin.genoox.com/), accessed on 30 March 2024. *Publication by the authors that included the same patient.

Figure legend

Figure 1. Germline mutations identified in patients. The Sanger sequencing chromatograms are presented for each heterozygous mutation (indicated by an asterisk) and surrounding nucleotides.

